Endocrinology, Vol 120, 1173-1178, Copyright © 1987 by Endocrine Society

ARTICLES

Measurement of 1,25-dihydroxyvitamin D3 receptor turnover by dense amino acid labeling: changes during receptor up-regulation by vitamin D metabolites

EM Costa and D Feldman

We have previously demonstrated that 1,25-dihydroxyvitamin D3 [1,25- (OH)2D3] receptors are up-regulated by exposure to 24,25-(OH)2D3 and other vitamin D metabolites in several mammalian cell cultures systems as well as in vivo in rats. The goal of the current study was to determine how changes in receptor turnover could give rise to increased receptor levels after treatment with 24,25-(OH)2D3, whether by an increased rate of synthesis or a decreased rate of degradation. Receptor turnover was studied by the dense amino acid shift technique in cultured pig kidney cells (LLC-PK1). In control cells, the half-life of the 1,25-(OH)2D3 receptor was estimated to be 4.3 +/- 0.4 h, with a degradation rate constant (kD) of 0.16 +/- 0.01 h-1. In parallel experiments, cells were treated with 24,25-(OH)2D3 for about 48 h to reach a new up-regulated steady state before the measurement of receptor turnover. In up-regulated cells, the receptor half-life was prolonged to 8.9 +/- 1.0 h and the kD was 0.07 +/- 0.01 h-1. Assuming a steady state, the values obtained for total receptor levels and the degradation rate allow calculation of the synthesis rate (kS) at equilibrium. Control cells synthesized receptors at the rate of 3.4 +/- 0.4 vs. up-regulated cells at 4.9 +/- 0.5 fmol mg protein-1 h-1. In conclusion, the data indicate that up-regulation of receptors after exposure of cells to vitamin D metabolites results predominantly from a prolongation of receptor half-life in addition to a relatively smaller increase in the rate of receptor synthesis.

This article has been cited by other articles:

				K. D. Healy, J. B. Zella, J. M. Prahl, and H. F. DeLuca Regulation of the murine renal vitamin D receptor by 1,25-dihydroxyvitamin D3 and calcium PNAS, August 19, 2003; 100(17): 9733 - 9737. [Abstract] [Full Text] [PDF]

				A. J. Brown, A. Dusso, and E. Slatopolsky Vitamin D Am J Physiol Renal Physiol, August 1, 1999; 277(2): F157 - F175. [Abstract] [Full Text] [PDF]

				J. Reichrath, J. Kamradt, X. Hong Zhu, X. Fu Kong, W. Tilgen, and M. F. Holick Analysis of 1,25-Dihydroxyvitamin D3 Receptors (VDR) in Basal Cell Carcinomas Am. J. Pathol., August 1, 1999; 155(2): 583 - 589. [Abstract] [Full Text] [PDF]

				L. H. Ly, X.-Y. Zhao, L. Holloway, and D. Feldman Liarozole Acts Synergistically with 1{alpha},25-Dihydroxyvitamin D3 to Inhibit Growth of DU 145 Human Prostate Cancer Cells by Blocking 24-Hydroxylase Activity Endocrinology, May 1, 1999; 140(5): 2071 - 2076. [Abstract] [Full Text]

				M. Friedrich, L. Rafi, W. Tilgen, W. Schmidt, and J. Reichrath Expression of 1,25-Dihydroxy Vitamin D3 Receptor in Breast Carcinoma J. Histochem. Cytochem., November 1, 1998; 46(11): 1335 - 1338. [Abstract] [Full Text]

				L. A. Crofts, M. S. Hancock, N. A. Morrison, and J. A. Eisman Multiple promoters direct the tissue-specific expression of novel N-terminal variant human vitamin D receptor gene transcripts PNAS, September 1, 1998; 95(18): 10529 - 10534. [Abstract] [Full Text] [PDF]